Overview
- Data from 3 Axis Advisors show more planned hikes than at this point last year, with the median increase around 4%.
- Pfizer leads with increases on about 80 products, including Ibrance, Nurtec, Paxlovid, and a 15% rise for COVID vaccine Comirnaty.
- A small set of products—about nine—will see list‑price cuts, including Jardiance, which Boehringer Ingelheim and Eli Lilly reduced by roughly two‑thirds after Medicare negotiations.
- The moves come as the Trump administration touts pricing deals with 14 manufacturers for some Medicaid and cash‑pay sales, even as broader list prices head higher.
- Reported changes take effect around January 1 and do not capture behind‑the‑scenes discounts negotiated by insurers and pharmacy benefit managers.